Overview

  • Product name

    Anti-TGF beta Receptor I antibody
    See all TGF beta Receptor I primary antibodies
  • Description

    Goat polyclonal to TGF beta Receptor I
  • Host species

    Goat
  • Tested applications

    Suitable for: IHC-P, WBmore details
  • Species reactivity

    Reacts with: Rat, Human
    Predicted to work with: Mouse, Rabbit, Horse, Cow, Dog, Pig, Rhesus monkey, Gorilla
  • Immunogen

    Synthetic peptide corresponding to Human TGF beta Receptor I aa 50-63 (internal sequence). Corresponds to NP_004603.1 and NP_001124388.1.
    Sequence:

    TDGLCFVSVTETTD

  • Positive control

    • WB: Rat liver tissue lysate. IHC-P: Human adrenal gland and small intestine tissues.

Properties

Applications

Our Abpromise guarantee covers the use of ab121024 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB Use a concentration of 0.1 - 0.3 µg/ml. Detects a band of approximately 55 kDa (predicted molecular weight: 55 kDa).

Target

  • Function

    On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta.
  • Tissue specificity

    Found in all tissues examined, most abundant in placenta and least abundant in brain and heart.
  • Involvement in disease

    Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 1A (LDS1A) [MIM:609192]; also known as Furlong syndrome or Loeys-Dietz aortic aneurysm syndrome (LDAS). LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.
    Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 2A (LDS2A) [MIM:608967]. LDS2 is an aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients.
    Defects in TGFBR1 are the cause of aortic aneurysm familial thoracic type 5 (AAT5) [MIM:608967]. Aneurysms and dissections of the aorta usually result from degenerative changes in the aortic wall. Thoracic aortic aneurysms and dissections are primarily associated with a characteristic histologic appearance known as 'medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance.
  • Sequence similarities

    Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
    Contains 1 GS domain.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications

    Phosphorylated at basal levels in the absence of ligand binding. Activated by multiple phosphorylation, mainly in the GS region.
  • Cellular localization

    Membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • AAT 5 antibody
    • AAT5 antibody
    • Activin A receptor type II like kinase 53kDa antibody
    • Activin A receptor type II like kinase, 53kD antibody
    • Activin A receptor type II like protein kinase of 53kD antibody
    • activin A receptor type II-like kinase, 53kDa antibody
    • activin A receptor type II-like protein kinase of 53kD antibody
    • Activin receptor like kinase 5 antibody
    • Activin receptor-like kinase 5 antibody
    • ACVRLK 4 antibody
    • ACVRLK4 antibody
    • ALK 5 antibody
    • ALK-5 antibody
    • ALK5 antibody
    • LDS1A antibody
    • LDS2A antibody
    • MSSE antibody
    • Serine/threonine protein kinase receptor R4 antibody
    • Serine/threonine-protein kinase receptor R4 antibody
    • SKR 4 antibody
    • SKR4 antibody
    • TbetaR I antibody
    • TbetaR-I antibody
    • TGF beta receptor type 1 antibody
    • TGF beta receptor type I antibody
    • TGF beta type I receptor antibody
    • TGF-beta receptor type I antibody
    • TGF-beta receptor type-1 antibody
    • TGF-beta type I receptor antibody
    • TGFBR 1 antibody
    • TGFBR1 antibody
    • TGFBR1 protein antibody
    • TGFR 1 antibody
    • TGFR-1 antibody
    • TGFR1 antibody
    • TGFR1_HUMAN antibody
    • Transforming growth factor beta receptor 1 antibody
    • Transforming growth factor beta receptor I (activin A receptor type II like kinase, 53kD) antibody
    • Transforming growth factor beta receptor I antibody
    • transforming growth factor, beta receptor 1 antibody
    • transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kD) antibody
    • Transforming growth factor-beta receptor type I antibody
    see all

Images

  • Anti-TGF beta Receptor I antibody (ab121024) at 0.1 µg/ml + Rat liver lysate (in RIPA buffer) at 35 µg

    Developed using the ECL technique.

    Predicted band size: 55 kDa


    Exposure time: 1 hour


    Primary incubation was 1 hour. Detected using chemiluminescence.

References

This product has been referenced in:

  • Lou LL  et al. (+)-Isobicyclogermacrenal and spathulenol from Aristolochia yunnanensis alleviate cardiac fibrosis by inhibiting transforming growth factor ß/small mother against decapentaplegic signaling pathway. Phytother Res 33:214-223 (2019). Read more (PubMed: 30375049) »
  • Yuan M  et al. Proteomic Analysis of Nucleus Pulposus Cell-derived Extracellular Matrix Niche and Its Effect on Phenotypic Alteration of Dermal Fibroblasts. Sci Rep 8:1512 (2018). IHC-P ; Rabbit . Read more (PubMed: 29367647) »
See all 2 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab121024.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up